Member area login
You don't have or don't remember the password!
Click Here
Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

--------------------

ISSN print: 0393 – 0564
ISSN digital: 0392- 7091



BC: Articoli scritti da A. Melegari

Il laboratorio di autoimmunità nella diagnosi di miopatia autoimmune necrotizzante indotta da statina
The autoimmunity laboratory in the diagnosis of necrotizing autoimmune myopathy induced by statins
<p>Statins have been recently associated with a necrotizing autoimmune myopathy (NAM) characterized by inflammation, myopathy and muscle necrosis and by the presence of anti 3-hydroxy-3-methylglutaryl-coenzim A reductase antibodies (anti-HMGCR). This case report describes a case of a man who was taking atorvastatin, complaining muscle weakness and creatine kinase (CK) very high levels. The main laboratory and autoimmunity tests (including the major myositis antibodies) were negative, despite a muscle biopsy showed a myopathic process. Because of these results the detection of anti-HMGCR antibody was activated and the positive result confirmed the diagnosis of NAM. The patient stopped the statin therapy and started a steroid therapy with improvement in muscle symptoms and mild decrease of CK. The role of the autoimmunity laboratory in the diagnostic path of this rare autoimmune disease is fundamental. Though statin-associated NAM is a rare entity, it should be considered in patients who continue to have CK elevation and muscle weakness during or after discontinuation of statin therapy.</p>
Biochimica Clinica ; 45(4) e27
Casi clinici - Case report
 
Una malattia neurologica di difficile inquadramento
A neurological disease difficult to classify
<p>We describe a case of a 32 year old woman visiting to the NeurologyUnit with progressive bi-frontal headache and reduced visual acuity followed by disequilibrium and dysarthria.<br />Cerebrospinal fluid (CSF) analysis documented pleyocitosis with slight CSF-blood-barrier damage.<br />Routine laboratory tests that were all negative except for the presence of serum anti-myelin oligodendrocyteglycoprotein (MOG) antibody.<br />Thanks to the laboratory test results, neurologists could classified the patient as a case of encephalomyelitis anti-MOG antibody related and have treated her with methylprednisolone followed by Rituximab with clinical improvementand reduction of brain lesion.<br />Anti-MOG antibody associated to encephalomyelitis is currently considerated as a distinct nosologic entityimmunopathogenetically identifiable among the neuromyelitis spectrum disorders.<br />The case illustrated here underlines the central role of the clinical laboratory for the correct diagnosis of demyelinatingnervous system diseases.</p>
Biochimica Clinica ; 43(3) e28-e30
Casi Clinici - Case Report
 
Determinazione e utilizzo clinico di autoanticorpi e/o di profili autoanticorpali nelle malattie epatiche autoimmuni – aggiornamento 2021
<p>Description and clinical use of autoantibody determination in autoimmune liver diseases &ndash; update 2021, on behalf of the Study Group &ldquo;Autoimmune Diseases&rdquo; of the Italian Society of Clinical Biochemistry. The autoantibody assessment in the field of autoimmune liver disease is crucial both for diagnosis and prognosis. Although these autoantibodies are sometime present even in the normal healthy individuals, their presence is a prerequisite to diagnose autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC); some of these autoantibodies are included in the diagnostic scoring system for these diseases. The laboratory diagnostics of autoimmune liver diseases, traditionally carried out using indirect immunofluorescence testing (IFT) on rodent tissue slices, has achieved substantial improvements due to innovative analytical opportunities, such as ELISA-based diagnostic assay and Multiple Immunodot Liver profile test based on recombinant or purified antigens. The aim of this document is to highlight the crucial role of the new antigen specific tests for a better diagnostic strategy in the field of the three major autoimmune liver diseases AIH, PBC and Primary sclerosing cholangitis (PSC).</p>
Biochimica Clinica ; 17(1)
Documenti - Documents